Literature DB >> 28475674

No benefit from the addition of anti-EGFR antibody in all right-sided metastatic colorectal cancer?

Y Sunakawa1, A Tsuji2, M Fujii3, W Ichikawa4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28475674     DOI： 10.1093/annonc/mdx231

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  7 in total

Review 1.  Colorectal Cancer: Why Does Side Matter?

Authors:  Claire Gallois; Simon Pernot; Aziz Zaanan; Julien Taieb
Journal:  Drugs       Date:  2018-06       Impact factor: 9.546

2.  Phase II Study of Panitumumab Monotherapy in Chemotherapy-Naïve Frail or Elderly Patients with Unresectable RAS Wild-Type Colorectal Cancer: OGSG 1602.

Authors:  Tetsuji Terazawa; Takeshi Kato; Masahiro Goto; Katsuya Ohta; Shingo Noura; Hironaga Satake; Yoshinori Kagawa; Hisato Kawakami; Hiroko Hasegawa; Kazuhiro Yanagihara; Tatsushi Shingai; Ken Nakata; Masahito Kotaka; Masayuki Hiraki; Ken Konishi; Shiro Nakae; Daisuke Sakai; Yukinori Kurokawa; Toshio Shimokawa; Taroh Satoh
Journal:  Oncologist       Date:  2020-09-28

3.  Negative Ultraselection of Patients With RAS/BRAF Wild-Type, Microsatellite-Stable Metastatic Colorectal Cancer Receiving Anti-EGFR-Based Therapy.

Authors:  Giovanni Randon; Giulia Maddalena; Marco Maria Germani; Chiara Carlotta Pircher; Paolo Manca; Francesca Bergamo; Mirella Giordano; Caterina Sposetti; Aldo Montagna; Guglielmo Vetere; Luca Zambelli; Cosimo Rasola; Alessandra Boccaccino; Filippo Pagani; Margherita Ambrosini; Marco Massafra; Gabriella Fontanini; Massimo Milione; Matteo Fassan; Chiara Cremolini; Sara Lonardi; Filippo Pietrantonio
Journal:  JCO Precis Oncol       Date:  2022-04

4.  Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial).

Authors:  Eiji Oki; Yasunori Emi; Takeharu Yamanaka; Hiroyuki Uetake; Kei Muro; Takao Takahashi; Takeshi Nagasaka; Etsuro Hatano; Hitoshi Ojima; Dai Manaka; Tetsuya Kusumoto; Yu Katayose; Toshiyoshi Fujiwara; Kazuhiro Yoshida; Michiaki Unno; Ichinosuke Hyodo; Naohiro Tomita; Kenichi Sugihara; Yoshihiko Maehara
Journal:  Br J Cancer       Date:  2019-07-09       Impact factor: 7.640

Review 5.  Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors.

Authors:  Jesús García-Foncillas; Yu Sunakawa; Dan Aderka; Zev Wainberg; Philippe Ronga; Pauline Witzler; Sebastian Stintzing
Journal:  Front Oncol       Date:  2019-09-20       Impact factor: 6.244

Review 6.  Recent advances in treatment for colorectal liver metastasis.

Authors:  Eiji Oki; Koji Ando; Ryota Nakanishi; Masahiko Sugiyama; Yuichiro Nakashima; Nobuhide Kubo; Kensuke Kudou; Hiroshi Saeki; Tadahiro Nozoe; Yasunori Emi; Yoshihiko Maehara
Journal:  Ann Gastroenterol Surg       Date:  2018-04-17

Review 7.  Should anti-EGFR mAbs be discontinued for conversion surgery in untreated right-sided metastatic colorectal cancer? A systematic review and meta-analysis.

Authors:  Datian Chen; Xiang Zhang; Guangyi Gao; Lili Shen; Jiaqi Xie; Xiaoping Qian; Huiyu Wang
Journal:  World J Surg Oncol       Date:  2018-10-08       Impact factor: 2.754
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.